[{"from": "human", "value": "Please give me some details about this molecule. [C][C@H1][Branch2][Ring1][N][C@@H1][C@H1][C][C][=Branch1][S][=C][Branch1][Branch2][N][Ring1][Branch1][C][Ring1][#Branch1][=O][C][=Branch1][C][=O][O][S][C][C][N][=C][N][O]"}, {"from": "gpt", "value": "The molecule is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to many beta-lactamases. Similar compounds include [meropenem], known for having greater activity against Gram negative bacteria, and the newer [ertapenem] which exhibits a longer half-life due to increased binding to plasma proteins. Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA. Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co."}]